文献速递腹部介入MRCT

胰腺癌立体定向放疗的系统综述:疗效、安全性与前景

Stereotactic body radiation therapy for pancreatic cancer: evaluating its efficacy, safety, and future prospects: systematic review.
PubMed 文献 · Br J Radiol · 2026-01-01

光子SBRT的1年局部控制率为70%-95%,中位总生存期13-20个月,≥3级急性毒性3%。高生物有效剂量、MRI自适应放疗及粒子治疗可提高局部控制并减少毒性,但远处进展仍为主要问题。

要点

  • 光子SBRT后1年局部控制率可达70%-95%,中位总生存期约13-20个月。
  • BED₁₀>70 Gy可改善局部控制,≥3级急性毒性约3%。
  • MRI自适应放疗可缩小边界至2-3 mm并降低约40%毒性,局部控制率>90%。

核心结论

  • 立体定向放疗在局部晚期胰腺癌中可提供较高局部控制率且毒性可接受。
  • 自适应MRI引导和粒子治疗可提高精度并减少毒性。
  • 远处进展发生率高,提示需要多模式联合治疗和大型随机试验。

研究设计与样本

  • 纳入≥20例、报告局部控制率、总生存期、无进展生存期和毒性的同行评议研究。
  • 采用Newcastle-Ottawa量表和Cochrane偏倚风险工具评估研究质量。
  • 因异质性较大,采用叙述性综合并参考近期遵循PRISMA指南的荟萃分析汇总估计值。

关键影像表现/征象

  • 光子SBRT后1年局部控制率为70%-95%,汇总估计为82%。
  • 远处进展占60%,是主要的失败模式。
  • 碳离子治疗报告1年局部控制率为95%。

诊断标准与关键数值

  • 光子SBRT中位总生存期为13-20个月,汇总估计为16.8个月。
  • BED₁₀>70 Gy与局部控制改善相关,风险比为0.68。
  • ≥3级急性毒性发生率为3%,晚期胃肠道毒性发生率为2%。
  • MRI自适应SBRT将照射边界缩小至2-3 mm,毒性降低约40%,局部控制率维持>90%。
  • 质子治疗中位总生存期为19.5个月。

临床应用与阅片要点

  • 对不适合手术的局部晚期胰腺癌患者,SBRT可作为局部控制手段之一。
  • MRI自适应SBRT可缩小照射边界并降低毒性,适合邻近胃肠道的高危病例。
  • 阅片随访时应重点关注远处转移,因远处进展是主要失败模式。

局限性

  • 纳入研究异质性较大,未进行统一定量合并。
  • 多数结论基于回顾性队列和近期荟萃分析,缺乏大型随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This systematic narrative review evaluates the efficacy, safety, and future potential of stereotactic body radiation therapy (SBRT) in locally advanced pancreatic cancer (LAPC), particularly for patients unsuitable for surgery.

METHODS: A systematic search of PubMed, Embase, and the Cochrane Library identified English and select non-English studies published between January 2010 and November 2025. Search terms included "pancreatic cancer," "SBRT," "LAPC," "adaptive radiotherapy," "proton therapy," "toxicity," and "outcomes." Eligible peer-reviewed studies (clinical trials, cohort studies, systematic reviews; ≥20 patients) reporting local control (LC), overall survival (OS), progression-free survival (PFS), and toxicity were included. Study quality was assessed using the Newcastle-Ottawa Scale and Cochrane Risk of Bias Tool. Owing to heterogeneity, narrative synthesis was performed, supplemented by pooled estimates from recent meta-analyses following PRISMA guidelines.

RESULTS: Thirty-five studies were included (25 photon SBRT, 6 protons, 4 carbon-ion). One-year LC ranged 70%-95% (pooled 82%); median OS 13-20 months (pooled 16.8 months). Higher biologically effective doses (BED₁₀) (>70 Gy) improved LC (HR 0.68). Grade ≥3 acute toxicity was 3%, and late gastrointestinal toxicity 2%. Adaptive MRI-guided SBRT reduced margins (2-3 mm) and toxicity (∼40%) while maintaining >90% LC. Proton therapy achieved mOS 19.5 months; carbon-ion therapy reported 95% 1-year LC. Distant progression (60%) predominated.

CONCLUSIONS: Stereotactic body radiation therapy provides high LC with acceptable toxicity in LAPC. Advanced adaptive and particle techniques enhance precision, but systemic progression remains the main challenge, underscoring the need for multimodal strategies and large randomized trials.

ADVANCES IN KNOWLEDGE: This article summarizes the efficacy of SBRT in LAPC.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Sarkar. Stereotactic body radiation therapy for pancreatic cancer: evaluating its efficacy, safety, and future prospects: systematic review. Br J Radiol. 2026. PMID: 42635528. doi:10.1093/bjr/tqag198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。